Biologics Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report By Product (Biologics, Biosimilar), By Service (Development Services, GMP Manufacturing, Fill-Finish & Packaging, Other Services), By Scale (Clinical, Commercial), By Type (Mammalian, Microbial), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Other End User) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Biologics Contract Development and Manufacturing Organization (CDMO) Market Size

The global biologics contract development and manufacturing organization market size was valued at USD 29.53 billion in 2025 and is projected to grow from USD 31.71 billion in 2026 to USD 56.00 billion by 2034, registering a CAGR of 7.37% during the forecast period from 2026 to 2034. North America dominated the biologics contract development and manufacturing organization market with a market share of 39.78% in 2025.

The biologics contract development and manufacturing organization (CDMO) market is witnessing strong expansion as pharmaceutical and biotech companies increasingly outsource the production of complex biologics to specialized service providers. Growth is primarily fueled by rising demand for monoclonal antibodies, biosimilars, ADCs, and cell and gene therapies, all of which require advanced bioprocessing technologies and single-use bioreactor systems. For instance, Samsung Biologics continues to expand large-scale multi-product antibody manufacturing capacity, while Lonza has developed integrated platforms for cell and gene therapy production. Additionally, increasing regulatory requirements from agencies such as the FDA and EMA are pushing companies toward compliant CDMO partnerships. Rising demand for faster clinical trial material supply is also accelerating adoption of automated biomanufacturing infrastructure worldwide.

By Product

The biologics segment is projected to grow at a CAGR of 8.21% during the forecast period, due to increasing demand for next-generation modalities like bispecific antibodies and ADCs, which require highly specialized manufacturing platforms. Expansion of single-use bioreactor adoption enables flexible and cost-efficient production of complex biologics with lower contamination risk.

The biosimilar segment is expected to grow at a CAGR of 8.46% during the forecast period, due to increasing patent expirations of major biologics, enabling faster market entry of cost-effective follow-on biologics. Expansion of regulatory pathways, such as interchangeability guidelines is improving substitution potential and physician acceptance. Rising demand from public healthcare systems to reduce biologics treatment costs is accelerating large-scale biosimilar adoption in oncology and autoimmune disease therapies.

Request Customizationto receive a tailored report.

By Service

GMP manufacturing segment dominates the market with a revenue share if 28.56% in 2025, due to stringent regulatory requirements for validated aseptic biologics production under FDA and EMA inspections, ensuring product safety and consistency. Expansion of multi-product GMP suites for monoclonal antibodies improves capacity utilization. Increasing demand for audit-ready digital batch documentation systems strengthens compliance and traceability in complex biologics manufacturing environments.

The fill-finish & packaging segment is expected to have the fastest growth, registering a CAGR of 9.31% during the forecast period. This growth is driven by increasing demand for prefilled syringes and ready-to-use injectable formats, especially for monoclonal antibodies and biologics requiring precise dosing. Expansion of high-speed aseptic isolator-based filling lines improves sterility assurance and production efficiency.

By Scale

The clinical segment is projected to grow at a CAGR of 9.35% during the forecast period, due to increasing outsourcing of early-phase biologics trials, especially adaptive Phase I/II studies that require rapid dose escalation and protocol flexibility. Expansion of decentralized clinical trial models for biologics improves patient recruitment efficiency and real-time data capture., and boosts segment growth

The commercial segment is expected to grow at a CAGR of 9.84% during the forecast period, due to increasing global launch of complex biologics such as monoclonal antibodies and biosimilars requiring large-scale GMP manufacturing and supply chain coordination. Rising demand for lifecycle management of approved biologics, including process optimization and post-approval scale-up, is driving sustained commercial manufacturing outsourcing and revenue growth.

By Type

The mammalian segment is estimated to grow at a CAGR of 8.19% during the forecast period, due to its strong suitability for producing complex recombinant biologics such as monoclonal antibodies, where proper protein folding and post-translational modifications are essential. Increasing demand for high-expression CHO cell-based systems is further driving adoption, as they ensure higher yield and product consistency.

The microbial segment is projected to grow at a CAGR of 9.05% during the forecast timeframe, owing to rapid production capability for recombinant proteins such as insulin, enzymes, and growth factors. Increasing adoption of bacterial and yeast expression systems enables faster scale-up compared to mammalian platforms. Strong demand for non-glycosylated biologics and industrial enzymes in pharmaceuticals and biotech manufacturing is further accelerating the use of microbial systems in large-scale production.

By End User

The pharmaceutical & biotechnology companies segment dominated the market with a revenue share of 68.19% in 2025. This dominance is attributed to extensive outsourcing of complex biologics like monoclonal antibodies, ADCs, and biosimilars, driven by limited in-house GMP capacity. They depend on CDMOs for full-cycle services from cell line development to commercial manufacturing, while growing oncology pipelines, cost efficiency needs, and faster market launch requirements further strengthen outsourcing demand.

The academic & research institutes segment is projected to grow at a CAGR of 10.12% during the forecast period due to higher funding for early-stage biologics and translational research in gene therapies and recombinant proteins. Strong university-CDMO collaborations accelerate scale-up from lab to clinical production. Government biotech grants and incubators further support innovation, increasing outsourcing of pilot manufacturing and process development to specialized CDMOs.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America: Market Leadership through Strong Presence of FDA Approval Systems and High Concentration of Biotech Companies

The North America biologics contract development and manufacturing organization (CDMO) market, which captured 39.78% of global revenue in 2025, is propelled by strong presence of FDA fast-track and breakthrough designation pathways, which accelerate outsourcing of clinical-to-commercial manufacturing. High concentration of biotech clusters in Boston-Cambridge and San Diego supports rapid CDMO-biotech collaboration for monoclonal antibodies and cell therapies. Growing investment from venture capital-backed biologics startups increases demand for CDMO services across early and late-stage biologics pipelines in the region. For example, Lila Sciences raised over $550 million in total funding backed by Flagship Pioneering and Nvidia’s venture arm, reflecting strong investor appetite for biologics-linked platforms.

The US market is growing due to the strong presence of CAR-T and gene therapy commercialization hubs in states like California and Massachusetts is driving high demand for specialized CDMO capacity. Strong enforcement of domestic biologics supply chain security under the “Buy American” and pandemic resilience policies, which is pushing pharmaceutical companies to localize manufacturing within US-based CDMO facilities. Increasing demand for onshore GMP capacity and reducing reliance on offshore production further support market growth.

The Canada biologics contract development and manufacturing organization (CDMO) market is supported by strong government-backed life sciences initiatives, such as the Strategic Innovation Fund, which promotes domestic biomanufacturing capacity and reduces dependency on imports. Another key driver is the presence of specialized academic-industry collaboration hubs in Toronto and Montreal, enabling faster translation of early biologics research into CDMO partnerships. Canada benefits from a highly skilled bioprocess engineering workforce trained through institutions like the University of Toronto and McGill, supporting advanced biologics production and process development capabilities.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific: Fastest Growth Driven by Expansion of Government-Supported Biomanufacturing and Growing Demand for Biosimilars

The Asia Pacific biologics contract development and manufacturing organization (CDMO) market is expected to register the fastest growth with a CAGR of 13.60% during the forecast period due to rapid expansion of government-supported biomanufacturing clusters in countries like China, South Korea, and Singapore, which offer tax incentives and dedicated biotech zones. Increasing dominance of biosimilar production, especially monoclonal antibody biosimilars in India and China, is also driving large-scale outsourcing to CDMOs. Additionally, cost-efficient manufacturing infrastructure and availability of high-capacity GMP facilities enable faster scale-up compared to Western markets, attracting global pharma companies to outsource clinical and commercial biologics production to the region.

The China biologics contract development and manufacturing organization (CDMO) market is expanding due to strong government support under the “Made in China 2025” and Healthy China initiatives, which prioritize domestic biologics self-sufficiency. Rapid approval acceleration by NMPA for innovative biologics and biosimilars is shortening commercialization timelines. The presence of large-scale integrated biomanufacturing parks in Shanghai and Suzhou enables high-capacity, cost-efficient production, attracting global and local biotech outsourcing demand.

Singapore biologics contract development and manufacturing organization (CDMO) market growth is supported by highly specialized government-linked “plug-and-play” GMP facility leasing models at Tuas Biomedical Park, allowing rapid scale-up without long construction cycles. The country’s strong focus on high-value biologics like cell culture-derived vaccines and recombinant proteins benefits from ultra-clean utility infrastructure designed for zero-contamination tolerance manufacturing.

Competitive Landscape

The biologics CDMO market is highly competitive and moderately consolidated, with a few global leaders controlling a significant share due to large-scale biomanufacturing capacity, advanced technology platforms, and strong regulatory compliance capabilities. Companies such as Lonza, Samsung Biologics, WuXi Biologics, and Fujifilm Diosynth Biotechnologies dominate through end-to-end services spanning cell line development, process optimization, and commercial manufacturing. Their competitive advantage is driven by continuous capacity expansion and long-term contracts with global pharma firms. Mid-sized CDMOs focus on niche areas like cell and gene therapy or biosimilars but face high entry barriers due to capital intensity and stringent regulatory requirements.

List of Key and Emerging Players in Biologics Contract Development and Manufacturing Organization (CDMO) Market